Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


Proton-pump inhibitors

PPIs linked to increased risk of death

Proton-pump inhibitors (PPIs) could be responsible for thousands of excess deaths every year, according to the authors of a recent study[1].

The research, published in the BMJ Open, found that people taking PPIs had a 25% increased risk of death compared with those taking H2-receptor antagonists, an alternative type of acid suppression therapy.

“People have the idea that PPIs are very safe because they are readily available, but there are real risks to taking these drugs, particularly for long periods of time,” said lead author Ziyad Al-Aly from the Washington University School of Medicine in St Louis, Missouri.

The researchers used data from the US Department of Veterans Affairs, including 349,312 people who began taking PPIs or H2 blockers and were followed up for a median of 5.7 years.

The team found that the risk of all-cause mortality increased among PPI users the longer they took them. For example, compared with those who received PPIs for less than a month, those who received them for up to three months had a 5% increased risk of death. But those who took the drugs for between a year and two years had a 50% increased risk of death.

The researchers say that PPIs are frequently used for indications and durations they have not been tested or approved for. They suggest that while their use should not be deterred where medically appropriate, they should be used more judiciously and for minimal durations.

“A lot of times, people get prescribed PPIs for a good medical reason but then doctors don’t stop it, and patients just keep getting refill after refill after refill,” said Al-Aly. “There needs to be periodic reassessments as to whether people need to be on these.” 

Previous research has also linked use of the drugs to a number of adverse outcomes, including kidney disease, dementia and bone fractures.

Citation: The Pharmaceutical Journal URI: 20203137

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

RPS publications

Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Xray of acid reflux causing chest pain

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.